TY  - JOUR
T1  - Investigation of Butaselmevit’s Acute and Chronic Toxicity in Laboratory Animals
A1  - Tetiana Martyshuk
A1  - Bogdan Gutyj
A1  - Oleg Vyshchur
A1  - Ihor Paterega
A1  - Volodymyr Kushnir
A1  - Oleksii Bigdan
A1  - Inna Bushueva
A1  - Volodymyr Parchenko
A1  - Evhenii Mykhailiuk
A1  - Oleksandr Aleksieiev
A1  - Natalia Tkachenko
JF  - Annals of Pharmacy Practice and Pharmacotherapy
JO  - Ann Pharm Pract Pharmacother
SN  - 3062-4436
Y1  - 2022
VL  - 2
IS  - 1
DO  - 10.51847/kMDaMfkr0C
SP  - 32
EP  - 38
N2  - This study aimed to investigate the hepatoprotective effects of potassium 2-((4-amino-5-(morpholinomethyl)-4H-1,2,4-triazole-3-yl)thio)acetate’s on tetracycline and viral hepatitis models in chickens. The intact Cobb 500 cross-broiler chickens were subjected to a biochemical analysis of their blood and liver serum. According to the specified specifications, each group of chickens was housed independently in a distinct cell in the same room with the same climatic characteristics. It was found that “Butaselmevit” had a dose-dependent effect on laboratory animals’ leukopoiesis, hematological profile, and function of the liver. Research on the model of tetracycline-induced hepatitis in chickens showed that the compound 2-((4-amino-5-(morpholinomethyl)-4H-1,2,4-triazole-3-yl)thio)acetate has a hepatoprotective effect that is comparable to that of the reference medication, Thiotriazolin®. According to the results of a biochemical study, in the model of infectious hepatitis, potassium 2-((4-amino-5- (morpholinomethyl)-4H-1,2,4-triazole-3-yl)thio) acetate is combined with the traditional antibiotic Enrofloxacin® to produce hepatoprotective effects. 
UR  - https://galaxypub.co/article/investigation-of-butaselmevits-acute-and-chronic-toxicity-in-laboratory-animals-i6zvneniobod77p
ER  -